cdc.gov/coronavirus

ACIP COVID-19 Vaccines Work Group

Dr. Matthew F. Daley, Work Group Chair

September 1, 2022
▪ COVID-19 

vaccinations are 

estimated to 

have prevented 

13.7-15.9 million 

deaths 

▪ This represents 

an estimated 

63% reduction in 

total COVID 

deaths globally

Global impact of the first year of COVID-19 vaccinations: 

Mathematical model of transmission and infection based on official reported 

COVID-19 deaths, 185 countries, December 2020—December 2021

Watson, Barnsley, Toor et al. Lancet Infectious Diseases. 22:9(P1293-1302). https://doi.org/10.1016/S1473-3099(22)00320-6
▪ Novavax COVID-19 vaccine is now recommended as a two dose primary 

series vaccination for people ages 12 years and older 

▪ 670,000 doses have been distributed across all US states and territories

▪ 3.2 million doses have been purchased by the US government 

▪ As of August 25th, 2022:

–14,559 doses have been administered 

–2,591 people have completed a two dose primary series

Novavax COVID-19 vaccine:

Updates on use of the protein subunit vaccine platform

COVID Data Tracker: https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-additional-dose-totalpop Accessed 8/26/22.
▪ Data from multiple clinical trials of bivalent boosters, including those with an 

Omicron component, demonstrating safety and immunogenicity in >1700 adults 

both with and without prior SARS-CoV-2 infection

– >1400 individuals received a bivalent vaccine with the Omicron component specifically

▪ Antigenic cartography and immunologic implications of SARS-CoV-2 variants

▪ Modeling of pandemic outcomes in varied scenarios, demonstrating potential 

impact of new variants and varying vaccine/booster coverage

▪ Rare events of myocarditis after COVID-19 vaccination 

▪ Epidemiology of COVID-19 disease and variants, including the currently dominant 

Omicron BA 4/5 variant

ACIP COVID-19 Work Group Meeting Review: August 2022

4

Reviewed extensive data regarding to bivalent boosters and context: 

Engaged in broad discussions regarding use of bivalent boosters in people 

of all age groups currently recommended to receive a booster 
▪ Epidemiology of COVID-19 & SARS-CoV-2 variants Dr. Scobie (CDC)

▪ Immunology of SARS-CoV-2 variants Dr. Thornburg (CDC)

▪ Updates to COVID-19 vaccine effectiveness Dr. Link-Gelles (CDC)

▪ Updates to COVID-19 vaccine safety Dr. Shimabukuro (CDC)

Break

PUBLIC COMMENT

Agenda: Morning of Thursday September 1st, 2022
▪ Moderna bivalent COVID-19 vaccine Dr. Das (Moderna)

▪ Pfizer-BioNTech bivalent COVID-19 vaccine Dr. Gruber (Pfizer)

Break

▪ Evidence to recommendations framework: Dr. Oliver (CDC)

Bivalent COVID-19 booster doses

▪ Clinical considerations update Dr. Hall (CDC), Dr. Twentyman (CDC)

▪ Discussion

VOTE:

Moderna COVID-19 vaccine, Bivalent, in individuals ages 18 years and older

Pfizer-BioNTech COVID-19 vaccine, Bivalent, in individuals ages 12 years and older

Agenda: Afternoon of Thursday September 1st, 2022
ACIP members

▪ Matthew Daley (chair)

▪ Beth Bell 

▪ Grace Lee

▪ Keipp Talbot

▪ Oliver Brooks

Ex-officio/government members

▪ FDA: Doran Fink, Rachel Zhang, Lucia Lee

▪ NIH: Chris Roberts

▪ IHS: Uzo Chukwuma

▪ DOD: Bryan Schumacher

▪ CMS: Jeff Kelman

▪ BARDA: Christine Oshansky

▪ HHS: David Kim

CDC Leads

▪ Sara Oliver

▪ Evelyn Twentyman

Work Group members

7

Liaisons

▪ AAFP: Jonathan Temte

▪ AAP: Sean O’Leary

▪ ACOG: Denise Jamieson (primary), 

Laura Riley (alternate)

▪ ACP: Jason Goldman

▪ ADS: Emily Kahn

▪ AGS: Ken Schmader

▪ AIM: Rob Shechter (primary), 

Jane Zucker (alternate)

▪ AMA: Sandra Fryhofer

▪ ANA: Kendra McMillan (primary), 

Ruth Francis (alternate)

▪ APhA: Michael Hogue

▪ ASTHO: Marcus Plescia

▪ CSTE: Susan Lett, Paul Cieslak, Christine 

Hahn

IDSA: Jeff Duchin (primary)

Liaisons, cont’d

▪ NACCHO: Matt Zahn (primary), 

Jeff Duchin (alternate)

▪ NACI: Matthew Tunis (primary),

Kelsey Young (alternate)

▪ NFID: Bill Schaffner (primary), 

Marla Dalton (alternate)

▪ NMA: Patricia Whitley-Williams

▪ SHEA: Marci Drees

Consultants

▪ Ed Belongia 

▪ Kathy Kinlaw 

▪ Dayna Matthew 

▪ Kathleen Neuzil 

▪ Stanley Perlman 

▪ Peter Szilagyi

▪ Jose Romero

▪ Hank Bernstein
▪ Sarah Meyer

▪ Elisha Hall

▪ Megan Wallace

▪ Danielle Moulia

▪ Lauren Roper

▪ Hannah Rosenblum

▪ Katherine Fleming-Dutra

▪ Monica Godfrey

▪ Susan Goldstein

▪ Mary Chamberland

▪ Stephen Hadler

▪ Valerie Morelli

▪ JoEllen Wolicki

▪ Melinda Wharton

▪ Jessica MacNeil

CDC participants

8

▪ Amanda Cohn

▪ Tamara Pilishvili

▪ Ruth Link-Gelles

▪ Heather Scobie

▪ Natalie Thornburg

▪ Tom Shimabukuro

▪ John Su

▪ Julianne Gee

▪ Karen Broder

▪ Naomi Tepper

▪ LeAnne Fox

▪ Rebecca Greco Kone

▪ Rita Helfand

▪ Jefferson Jones

▪ Yvonne Bolen

▪ Meg Freedman

▪ Katherine Grusich

▪ Kristen Nordlund

▪ Amanda Dudley

▪ Sierra Scarbrough

▪ Joy Hsu

▪ Tara Anderson

▪ Amy Rubis

▪ Roodly Archer

▪ Andrew Kroger

▪ Lauri Markowitz

▪ Erin Kennedy

▪ Ryan Wiegand 

▪ Patricia Yu

▪ Yon Yu
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the 

official position of the Centers for Disease Control and Prevention.

Thank you!